Nogo receptor (NgR) is common in myelin-derived molecules, i.e., Nogo, MAG, and OMgp, and plays important roles in both axon fasciculation and the inhibition of axonal regeneration. In contrast to NgR's roles in neurons, its roles in glial cells have been poorly explored. Here, we found a dynamic regulation of NgR1 expression during development and neuronal injury. NgR1 mRNA was consistently expressed in the brain from embryonic day 18 to postnatal day 25. In contrast, its expression significantly decreased in the spinal cord during development. Primary cultured neurons, microglia, and astrocytes expressed NgR1. Interestingly, a contusion injury in the spinal cord led to elevated NgR1 mRNA expression at the injury site, but not in the motor cortex, 14 days after injury. Consistent with this, astrocyte activation by TGFb1 increased NgR1 expression, while microglia activation rather decreased NgR1 expression. These results collectively suggest that NgR1 expression is enhanced in a milieu of neural injury. Our findings may provide insight into the roles of NgR1 in glial cells.
INTRODUCTION
Neuronal axons in the central nervous systems (CNS) of adult mammals barely regenerate after injuries. This is due to neurons' low intrinsic capacity for regeneration and to the emergence of inhibitors. 1) These inhibitors can be categorized into three classes: (1) guidance molecules, e.g., ephrins and semaphorins, (2) myelin-derived molecules, i.e, Nogo, MAG (myelin-associated glycoprotein), and OMgp (oligodendrocyte myelin glycoprotein), and (3) chondroitin sulfate and keratan sulfate proteoglycans. [1] [2] [3] [4] [5] Among these, historically, myelin-derived molecules have been extensively studied. Nogo, MAG, and OMgp share the common receptor Nogo receptor (NgR). 6, 7) NgR is a glycophosphatidylinositol-linked protein 8) with three isotypes: NgR1, 2, and 3. 9, 10) These three are differentially expressed in CNS, but NgR1 is the most prominent one. 11) NgR1 has been implicated in axon fasciculation. 12) Thus, neutralizing antibody to NgR1 increases fasciculation and decreases the branching of cultured dorsal root ganglion neurons. This phenomenon is also observed in antibody to Nogo or Nogo knockout, suggesting that the Nogo-NgR1 axis suppresses axonal fasciculation.
Therefore, the functions of NgR1 have been extensively studied in neurons. However, NgR1 may be also expressed in other cell types. Here, we highlight NgR1 expressed in glial cells.
MATERIALS AND METHODS

Primary culture
Primary cultured neurons were prepared from the cerebellar granule neurons (CGNs) of postnatal day 7 Sprague Dawley WT rats. The meninges of the brain were carefully removed with fine forceps, and the remaining tissues were minced and digested using a Papain Dissociation System (Worthington, Lakewood, NJ, USA). Dissociated cells were applied to a 35/60% two-step Percoll gradient and centrifuged at 3000×g for 15 min. Cerebellar granule neurons at the interface were collected. Cells were suspended in Neurobasal medium (Invitrogen, Carlsbad, CA, USA) supplemented with 2 % B27 (Invitrogen), 2 mM glutamine, an additional 20 mM KCl, 50 U/ml penicillin, and 50 μg/ml streptomycin. 13) Primary cultured glial cells were prepared from the cortexes of postnatal day 1 WT rats. The whole brain was removed aseptically from the skull and the meninges were excised carefully under a dissecting microscope. The brain was strained through sterile mesh, and small pieces of tissues were cultured in flasks in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum, then incubated at 37 ºC in a humidified atmosphere containing 5% CO2. The culture medium was renewed every 7 days. The mixed glia cultured for 3 weeks was shaken at 120 rpm on a gyratory shaker for 6 hours. More than 95% of adhering cells were glial fibrillary acidic protein (GFAP)-positive astrocytes. The detached cells were reseeded in fresh culture dishes, and any contaminated oligodendrocyte progenitors were removed by changing the DMEM after 15 min incubation. More than 95% of the cells were found to be CD11b-positive. 14) Astrocytes (7×10 5 cells/ml) and microglia (7×10 5 cells/ml) was additionally cultured for 24 h in serum-free DMEM. Astrocytes were stimulated with TGF-b (Peprotech, London, UK) 5 ng/ml, 10 ng/ml, and 20 ng/ml and with EGF (Peprotech) 10 ng/ml and 20 ng/ml. After stimulation with cytokines for 48 hr, cells were collected. Microglia were stimulated with LPS (100 ng/ml).
Immunocytochemistry
The primary cultured cells were fixed for 1 min with 4% paraformaldehyde in 0.1 M phosphate buffer (Wako, Osaka, Japan) at room temperature. After several washes, they were solubulized in PBS with 0.1% Triton X-100 and incubated overnight at room temperature with the following primary antibodies: mouse monoclonal anti-Neuronal ClassIII b-Tubulin (Tuj1) antibody (1:500; Covance, Princeton, NJ, USA), mouse monoclonal anti-CD11b antibody (1:500; BD bioscience, Franklin Lakes, NJ, USA), mouse monoclonal anti-GFAP antibody (1:200; Sigma-Aldrich, St. Louis, MO, USA), and rabbit polyclonal anti-Nogo receptor (NgR1) antibody (1:200; abm, Richmond, BC, Canada). After three rinses with PBS, the cells were incubated for 60 min at room temperature with the following secondary antibodies: Alexa Fluor 594-conjugated goat anti-rabbit (Invitrogen), and Alexa Fluor 488-conjugated donkey anti-mouse (Invitrogen). The cells were rinsed in PBS, mounted with Fluorsave (Calbiochem, San Diego, CA, USA), and observed under a BZ-9000 fluorescence microscope (Keyence, Osaka, Japan).
RT-PCR and Quantitative RT-PCR
Total RNA was extracted from the rat brain, spinal cord, and primary cultured cells using an RNeasy Lipid Tissue kit and RNeasy Mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer's recommendations. cDNA was prepared from 1 μg of total RNA by using a Transcriptor First Strand cDNA Synthesis kit (Roche Diagnostics, Mannheim, Germany) following the standard protocols. The cDNA products were used for reverse-transcription polymerase chain reaction (PCR) and quantitative real-time PCR (QRT-PCR). QRT-PCR was performed on M×3000P (Agilent Technologies, Santa Clara, CA, USA) using synthetic primers and SYBR Green (Agilent Technologies). Samples were subjected to 45 cycles of amplification at 95˚C for 15 s and 60˚C for 30 s after holding 68˚C for 15 s and 95˚C for 1 min. Relative expression was calculated using the 2-(Ct experimental sample-Ct internal control sample (GAPDH)) method. The primer sequences used are listed in Table 1 .
Animal Surgery
Adult female Sprague Dawley (SD) rats weighing 200-230 g were used in the study of spinal cord injuries (SCI). The animals were anesthetized with an intraperitoneal injection of Somnopentyl (Kyoritsu Seiyaku, Tokyo, Japan). After Th 9 laminectomy, we exposed the dura mater and induced injury using a force of 200 kdyn using a commercially available SCI device (Infinite Horizon Impactor; Precision Systems and Instrumentation, Lexington, KY, USA) that provided a consistent degree of spinal cord contusion injury. All injuries included the dorsal CST and dorsal gray matter. After SCI was induced, the muscles and skin were closed in layers. The bladder was compressed by manual abdominal pressure twice daily until bladder function was restored. Food was provided on the cage floor, and the rats had no difficulty reaching their water bottles. All animals were given antibiotics in their drinking water [1.0 ml of Bactrim (Roche, Basel, Swiss Confederation) in 500 ml of acidified water] for 2 weeks after SCI. We excluded the rats without complete paraplegia on the next day after operation in all groups, as they were inappropriate for further evaluation. Animal care and experimental procedures were approved by the Animal Experimentation Committee of the Nagoya University Graduate School of Medicine and were conducted according to the Nagoya University Regulations for Experiments.
Statistical analysis
We performed statistical analysis using SPSS software (SPSS, Chicago, IL, USA). 
RESULTS
NgR1 expression during development
NgR1 mRNA expression was estimated by quantitative RT-PCR. NgR1 mRNA was consistently expressed in the brain from embryonic day 18 to postnatal day 25 (Fig. 1A) . In contrast, the spinal cord showed a striking decrease in NgR1 expression during development (Fig. 1B) . Thus, NgR1 expression is differentially regulated in the brain and spinal cord during development.
To identify the source of NgR1 expression, we primary cultured cerebellar granule neurons from P7 rats, and astrocytes and microglia from the brain cortex of P1 rats. As shown in Fig.  2 , all these cells expressed NgR1. These results suggest that not only neurons but also glial cells could be the source of NgR1 expression.
NgR1 expression after SCI
To address NgR1 expression regulation in a pathological condition, we employed a model of SCI. A contusion injury was made at thoracic level 9. Since NgR1 expressed in neurons plays an important role in the inhibition of axonal regeneration/sprouting, we expected that the SCI might influence its expression in the upper motor neurons. To address this question, the motor cortex area was removed after the SCI and subjected to analysis. However, the injury did not affect NgR1 expression in the motor cortex (Fig. 3A) . We then examined the spinal cord, removing the injury site (5 mm length) for analysis. Interestingly, NgR1 mRNA expression at the injury site was elevated at 14 days after SCI (Fig. 3B) .
Enhanced NgR1 expression in activated astrocytes
Elevated NgR1 expression at the injury site 14 days after SCI suggests that NgR1 expression may be regulated by glial activation. To address this hypothesis, we employed in vitro activation models of glial cells. TGFb1 increased NgR1 expression in primary cultured astrocytes (Fig. 4A) . The expression of neurocan, a hallmark of astrocyte activation, was also enhanced by TGFb1 ( Fig. 4B) . In contrast, microglia activation induced by LPS rather decreased NgR1 expression, while the other markers, CD86, TNF-a, and IFN-g were increased in this activation (Fig. 4C ).
DISCUSSION
We found that NgR1 is differentially expressed in the brain and the spinal cord during development. Thus, while NgR1 is consistently expressed in the brain, its expression is significantly downregulated in the spinal cord as development proceeds. Therefore, NgR1 expression is at its lowest level in the adult spinal cord. However, SCI enhances its expression at the injury site 14 days after injury. In contrast, NgR1 mRNA expression is not affected in the motor cortex after SCI. These results collectively suggest that SCI influences NgR1 expression in neural cells including glial cells but not in upper motor neurons. Consistent with this idea, in vitro activation of astrocytes enhances NgR1 expression. But microglial activation rather decreases its expression. Therefore, our data collectively suggest that glial cells should be taken into consideration if we address the roles of NgR1 in the nervous system.
The axis of Nogo, MAG, Omgp, and NgR1 has been extensively studied with regard to the inhibition of axonal regeneration/sprouting. Also, NgR1 has been implicated in axon fasciculation. Thus, the functions of NgR1 have been attributed to NgR1 expressed in neurons. Our present study highlighted NgR1 expressed in glial cells, particularly astrocytes. Although its biological roles during neural injuries and/or their recovery processes remain to be further investigated, NgR1 expressed in activated astrocytes should be examined. In this context, it is noteworthy that NgR1 is expressed in immune cells, i.e., B cells, T cells, and monocytes, in multiple sclerosis. Although Nogo does not influence the proliferation or the cytokine production of these cells, myelin containing Nogo reduces adhesion and enhances motility. In this way, NgR1 on immune cells may be involved in pathogeneses under the condition of immune cell activation, such as multiple sclerosis. 15) In addition, a slow induction of NgR1 (14 days after SCI) was unexpected. Although we could not investigate whether this expression was transient or continue to express thereafter, this question is important to be addressed in a future study.
Our findings of NgR1 expression during development are consistent with previous reports. Thus, it was reported that, although NgR1 mRNA estimated by in situ hybridization is diffusely expressed in the fetal mouse brain and spinal cord, its expression is not detected in the adult mouse spinal cord.
11) NgR1 mRNA expression is also not detected in the spinal cord of adult rat and human. 11, 16) We also found that, although TGFb1 increased NgR1 expression, EGF, another activator of astrocytes, did not enhance NgR1 expression in astrocytes (data not shown). This suggests that a specific signaling mediated by some insults, such as TGFb1, can activate astrocytes and enhance NgR1 expression. Regarding intracellular signaling through NgR1 in a milieu of neural injury, it is known that upon binding of myelin-derived molecules (MAG, Nogo and OMgp) or CSPG, NgR1 makes a complex with p75 and Lingo-1 on neurons. The NgR1 complex activates Rho-GTPase and consequently inhibit axon regeneration.
3) In addition to this intracellular signaling in neurons, NgR1 also contribute to oligodendrocyte differentiation where Myocilin, a glycoprotein secreted by astrocytes, binds to NgR1/Lingo-1 complex and suppresses Rho-GTPase in oligodendrocytes. 17) However, little is known about the significance of NgR1 expression in astrocytes. Our study demonstrate that astrocytes express NgR1 at least in vitro. Considering that intercellular cross-talk between glial cells and neurons plays a pivotal role in neuronal network reconstitution and functional recovery after SCI, NgR1 expressed in astrocytes would be an important subject for future studies.
